Lab-made antibodies can stop a migraine before it starts
By neutralizing a specific protein before it can dilate blood vessels, these lab-grown molecules can stop a three-day agony just hours after a single infusion.
Most migraine treatments were discovered by sheer accident. For decades, doctors repurposed blood pressure pills or antidepressants, hoping to stumble upon relief for a condition that affects one billion people. Eptinezumab represents a fundamental shift: it is a monoclonal antibody, a custom-designed protein grown in a lab to seek and destroy a single target. It hunts for CGRP, a neuropeptide that acts like a chemical flare in the brain. During an attack, this chemical floods the system, forcing blood vessels to widen and cranking up the volume on pain signals until the simple act of existing becomes unbearable.